A pilot study investigates empagliflozin for Lafora disease, providing initial electroclinical and FDG-PET findings over six months. This first-in-human study explores potential therapeutic avenues for this rare condition.
empagliflozin in lafora disease a first in human 6 month pilot study with electroclinical and fdg pet findings
Original title: “Empagliflozin in Lafora disease: A first-in-human 6-month pilot study with electroclinical and FDG-PET findings.”